Initial evaluation of hot flashes should include thyroid function testing and, when relevant, pregnancy testing
CrossRef Therapeutic modulation of the gut-liver axis with faecalibacterium prausnitzii in metabolic dysfunction-associated steatohepatitis Han Chen, Yan Wang, Wei Su, Yicheng Liu, Shuo Li, Yun Liu, Xiaoying Zhou BMC Microbiology .2026;[Epub] CrossRef MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Daz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism .2026;[Epub] CrossRef Prebiotic modulation of FMT donor microbiota enhances MASLD-relevant taxa and functions in an in vitro gut model Kait F Al, Suyang Jia, Michael Silverman, Gregor Reid, Jeremy P Burton, Seema Nair Parvathy Journal of Applied Microbiology .2026;[Epub] CrossRef Association of gut microbiota dietary index with MAFLD and the risk of liver fibrosis: the mediating effect of vitamins Jinlu Han, Teng Zhou, Jiong Chen, Ling Xu, Wen Shan, Qinghui Zhang Journal of Nutritional Science .2026;[Epub] CrossRef The MicrobiomeGutLiver Axis Drives PostKasai Fibrosis in Biliary Atresia: From Mechanism to Precision Intervention Jiwen Cheng Hepatology Research .2026
These trials included individuals who were in varying degrees of renal failure
The SURMOUNT-5 trial published in the New England Journal of Medicine in May 2025 was the first randomized, head-to-head comparison of the two medications in patients with obesity but without type 2 diabetes
